Effects of alendronate or alfacalcidol on bone metabolic indices and bone mineral density in patients with ophthalmologic disease treated with glucocorticoid

References

• Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15(6):993–1000.
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13(10):777–87.
   PubMed Web of Science ®Google Scholar
• Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int. 2004;15(4):323–8.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton LJ III, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19(6):893–9.
   PubMed Web of Science ®Google Scholar
• Kaji H, Sugimoto T, Kanatani M, Nishiyama K, Chihara K. Dexamethasone stimulates osteoclast-like cell formation by directly acting on hemopoietic blast cells and enhances osteoclast-like cell formation stimulated by parathyroid hormone and prostaglandin E2. J Bone Miner Res. 1997;12(5):734–41.
   PubMed Web of Science ®Google Scholar
• Iu MF, Kaji H, Sowa H, Naito J, Sugimoto T, Chihara K. Dexamethasone suppresses Smad3 pathway in osteoblastic cells. J Endocrinol. 2005;185(1):131–8.
   PubMed Web of Science ®Google Scholar
• Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18:1319–28.
   PubMed Web of Science ®Google Scholar
• Kaji H, Yamauchi M, Chihara K, Sugimoto T. Glucocorticoid excess affects cortical bone geometry in premenopausal, but not posetmenopausal, women. Calcif Tissue Int. 2008;82(3):182–90.
   PubMed Web of Science ®Google Scholar
• Kaji H, Yamauchi M, Chihara K, Sugimoto T. Relationship between endogenous parathyroid hormone and bone metabolism/geometry in female patients treated with glucocorticoid. Horm Metab Res. 2008;40(1):60–5.
   PubMed Web of Science ®Google Scholar
• Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333(22):1437–43.
   PubMed Web of Science ®Google Scholar
• Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, et al. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 2002;23(4):508–16.
   PubMed Web of Science ®Google Scholar
• Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, et al. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev. 2002;23(4):517–23.
   PubMed Web of Science ®Google Scholar
• Kaji H, Hisa I, Inoue Y, Naito J, Sugimoto T, Kasuga M. Analysis of factors affecting increase in bone mineral density at lumbar spine by bisphosphonate treatment in postmenopausal osteoporosis. J Bone Miner Metab. 2009;27(1):76–82.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280(24):2077–82.
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Thompson DE, Black DM, Quandt SA, Cauley J, Geusens P, et al. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. J Bone Miner Res. 2005;20(6):971–6.
   PubMed Web of Science ®Google Scholar
• Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333(22):1437–43.
   PubMed Web of Science ®Google Scholar
• Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med. 1998;339(5): 292–9.
   PubMed Web of Science ®Google Scholar
• Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids. A randomized, double-blind, placebo-controlled extension trial.Arthritis Rheumat. 2001;44(1):202–11.
   PubMedGoogle Scholar
• Amin S, Lavalley MP, Simms RW, Felson DT. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res. 2002; 17(8):1512–26.
   PubMed Web of Science ®Google Scholar
• de Nijs RNJ, Jacobs JWG, Lems WF, Laan RF, Algra A, Huisman AM, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med. 2006;355(7):675–84.
   PubMed Web of Science ®Google Scholar
• Kaji H, Kuroki Y, Murakawa Y, Funakawa I, Funasaka Y, Kanda F, Sugimoto T .Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocortiocid: a prospectivbe study. Osteoporos Int. 2010;21(9): 1565–71.
   PubMed Web of Science ®Google Scholar
• Alele JD, Kamen DL. The importance of inflammation and vitamin D status in SLE-associated osteoporosis. Autoimmun Rev 2010;9(3):137–9.
   PubMed Web of Science ®Google Scholar
• Locascio V, Bonucci E, Imbimbo B, Ballanti P, Adami S, Milani S, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner. 1990;8(1):39–51.
   PubMedGoogle Scholar
• Chohen D, Adachi JD. The treatment of glucocorticoid-induced oteoprosis. J steroid Biochem Mol Bio. 2004;88(4–5):337–49.
   PubMed Web of Science ®Google Scholar
• Okada Y, Nawata M, Nakayamada S, Nakayamada S, Saito K, Tanaka Y. Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocortiocoid therapy. J Rheumatol. 2008;35(11):2249–54.
   PubMed Web of Science ®Google Scholar
• Haugeberg G, Griffiths B, Sokoll KB, Emery P. Bone loss in patients treated with pulses of methylprednisolone is not negligible: a short term prospective observational study. Ann Rheum Dis. 2004; 63(8):940–4.
   PubMed Web of Science ®Google Scholar
• Jacobs JW, de Nijs RN, Lems WF, Geusens PP, Laan RF, Huisman AM, et al. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of changes in bone mineral density, bone markers, and calcium homeostasis. J Rheumatol. 2007;34(5):1051–7.
   PubMed Web of Science ®Google Scholar
• Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J Bone Miner Res. 2000;15(8):1526–36.
   PubMed Web of Science ®Google Scholar
• Kaji H, Yamauchi M, Yamaguchi T, Sugimoto T. Urinary deoxypyridinoline is a BMD-independent marker for prevalent vertebral fractures in postmenopausal women treated with glucocorticoid. Osteoporos Int. 2010;21(9):1585–90.
   PubMed Web of Science ®Google Scholar
• Kaji H, Yamauchi M, Chihara K, Sugimoto T. The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis. Endor J. 2006;53(1):27–34.
   Google Scholar
• Burshell AL, Moricke R, Correa-Rotter R, Chen P, Warner MR, Dalsky GP, et al. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone. 2010;46(4):935–9.
   PubMed Web of Science ®Google Scholar
• Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927–38.
   PubMed Web of Science ®Google Scholar
• Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004; 350(12):1189–99.
   PubMed Web of Science ®Google Scholar
• Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, et al. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Osteoporos Int. 2012;23(3):1083–90.
   PubMed Web of Science ®Google Scholar
• Hayashi K, Yamamoto M, Murakawa Y, Yamauchi M, Kaji H, Yamaguchi T, Sugimoto T. Bone fragility in male glucocorticoid-induced osteoporosis is not defined by bone mineral density. Osteoporos Int. 2009;20(11):1889–1894.
   PubMed Web of Science ®Google Scholar
• Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int. 2009;20(12):2095–104.
   PubMed Web of Science ®Google Scholar